NasdaqCM:ALBO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Albireo Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALBO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.7%

ALBO

-1.0%

US Biotechs

-1.2%

US Market


1 Year Return

93.4%

ALBO

39.3%

US Biotechs

19.5%

US Market

Return vs Industry: ALBO exceeded the US Biotechs industry which returned 39.3% over the past year.

Return vs Market: ALBO exceeded the US Market which returned 19.5% over the past year.


Shareholder returns

ALBOIndustryMarket
7 Day-6.7%-1.0%-1.2%
30 Day-11.8%2.8%5.8%
90 Day30.8%-2.8%8.1%
1 Year93.4%93.4%41.8%39.3%22.3%19.5%
3 Year28.2%28.2%20.0%14.0%43.6%34.0%
5 Yearn/a21.2%12.5%87.3%66.1%

Price Volatility Vs. Market

How volatile is Albireo Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Albireo Pharma undervalued compared to its fair value and its price relative to the market?

5.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ALBO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ALBO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ALBO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALBO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALBO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALBO is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Albireo Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

59.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALBO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALBO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALBO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ALBO's revenue (69.1% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: ALBO's revenue (69.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Albireo Pharma performed over the past 5 years?

-48.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALBO is currently unprofitable.

Growing Profit Margin: ALBO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALBO is unprofitable, and losses have increased over the past 5 years at a rate of 48.6% per year.

Accelerating Growth: Unable to compare ALBO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: ALBO has a negative Return on Equity (-91.48%), as it is currently unprofitable.


Next Steps

Financial Health

How is Albireo Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ALBO's short term assets ($160.0M) exceed its short term liabilities ($17.2M).

Long Term Liabilities: ALBO's short term assets ($160.0M) exceed its long term liabilities ($77.7M).


Debt to Equity History and Analysis

Debt Level: ALBO's debt to equity ratio (10.5%) is considered satisfactory.

Reducing Debt: ALBO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALBO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ALBO has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 47.2% each year.


Next Steps

Dividend

What is Albireo Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALBO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALBO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALBO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALBO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALBO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Ron Cooper (57 yo)

5.25yrs

Tenure

US$2,995,406

Compensation

Mr. Ronald H. W. Cooper, also known as Ron, has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 2015. Mr. Cooper has spent more than 25 years at Bristol-Myers Squibb, where ...


CEO Compensation Analysis

Compensation vs Market: Ron's total compensation ($USD3.00M) is about average for companies of similar size in the US market ($USD2.82M).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ronald H. Cooper
CEO, President & Director5.25yrsUS$3.00m0.046%
$ 301.2k
Patrick Horn
Chief Medical Officer2.25yrsUS$1.11m0.023%
$ 150.1k
Pamela Stephenson
Chief Commercial Officer1.58yrsUS$1.96m0.12%
$ 767.4k
Per-Goran Gillberg
Co-Founder & VP of Developmentno datano datano data
Jan Mattsson
Chief Scientific Officer & MD (Sweden) and Co-Founderno dataUS$1.40m0.13%
$ 830.8k
Simon Harford
CFO & Treasurer2yrsno data0.024%
$ 158.4k
Jason Duncan
Chief Legal Officer2.33yrsno data0.020%
$ 132.8k
Michelle Graham
Chief Human Resources Officer0.92yrno datano data
Kristina Torfgård
VP & Global Project Headno datano datano data
Martha Carter
Chief Regulatory Officer3.92yrsUS$1.24m0%
$ 0
Paresh Soni
Consultant2.25yrsUS$1.06mno data

2.3yrs

Average Tenure

57yo

Average Age

Experienced Management: ALBO's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ronald H. Cooper
CEO, President & Director5.25yrsUS$3.00m0.046%
$ 301.2k
Roger Jeffs
Independent Director3.08yrsUS$168.07k0%
$ 0
David Chiswell
Independent Chairman of the Board12.67yrsUS$193.07k0.30%
$ 1.9m
Davey Scoon
Independent Director3.92yrsUS$179.32k0%
$ 0
Michael Gutch
Independent Director5yrsUS$179.32k0%
$ 0
Anne Klibanski
Independent Director2.33yrsUS$160.57k0%
$ 0
Stephanie Okey
Independent Director2.33yrsUS$164.32k0%
$ 0

3.9yrs

Average Tenure

60yo

Average Age

Experienced Board: ALBO's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.7%.


Top Shareholders

Company Information

Albireo Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Albireo Pharma, Inc.
  • Ticker: ALBO
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$651.571m
  • Shares outstanding: 18.99m
  • Website: https://www.albireopharma.com

Number of Employees


Location

  • Albireo Pharma, Inc.
  • 10 Post Office Square
  • Suite 1000 South
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BDQMDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2016
ALBONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2016

Biography

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. It ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 00:57
End of Day Share Price2020/10/19 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.